Chris Hancock elected as a Fellow of Royal Academy
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Chris Hancock elected as a Fellow of Royal Academy of Engineering
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that its Founder and Chief Technology Officer, Professor Chris Hancock, has been elected as a Fellow of the Royal Academy of Engineering (RAEng).
The Royal Academy of Engineering has elected 72 leading figures in the field of engineering and technology to its Fellowship. The group comprises 60 Fellows, seven International Fellows and five Honorary Fellows, each of whom has made exceptional contributions to their own sector, pioneering new innovations, leading progress in business or academia, providing high level advice to government, or promoting wider understanding of engineering and technology.
Chris has over 25 years of experience in medical device development. He holds a personal Chair in the Medical Microwave Systems Research Group at Bangor University, where he developed a new course in microwave engineering applied to medicine, and has supervised and mentored a number of students that have gone on to become key members of the Creo Medical engineering team (many have gained higher degrees under his supervision). He is a Fellow of the Institute of Physics, a Chartered Physicist, Fellow of the Institute of Engineering and Technology, a Chartered Engineer and a Senior Member of the IEEE. He also became a Fellow of the Learned Society of Wales in 2022. Chris is a named inventor and lead author on over 1200 patents/patent applications and journal publications, and in 2019 was named in the Sunday Times' Maserati 100 annual list of inspiring entrepreneurs, and awarded the Institute of Physics Katherine Burr Blodgett Gold Medal and Prize for his work in electrosurgery.
Chris was also appointed as a Royal Academy of Engineering Visiting Professor at UCL in July 2019, and has since given presentations/lectures on how engineering and medicine can be brought together to develop products that produce better clinical outcomes for patients all over the world. He also mentored a number of undergraduate and postgraduate students interested in developing start-up businesses.
The new Fellows will be formally admitted to the Academy at a special ceremony in London on 8 November, when each Fellow will sign the roll book. In joining the Fellowship, they will add their unique capabilities to the Academy's mission to harness the power of engineering to create a sustainable society and an inclusive economy for all.
Chris Hancock, Chief Technology Officer and Founder of Creo Medical, said: "It is a great honour to be elected to the Fellowship of the Royal Academy of Engineering, and to join a group of individuals who have contributed so much to the field. I am truly humbled and incredibly grateful for the acknowledgement and support I have received from my peers."
Sir Jim McDonald FREng FRSE, President of the Royal Academy of Engineering, said: "I am delighted to welcome such an array of enormously talented people to the Fellowship of the Royal Academy of Engineering. From industry and enterprise to education and government - both national and international - these are some of our most pioneering and distinguished engineers and technologists.
"In an uncertain world, one thing is certain - engineering skills, vision and leadership will play a crucial part in addressing the escalating domestic and global challenges that we face today. The combined connectivity, professionalism, experience and wisdom of the new Fellows who join us today will greatly enrich the expertise and support we can provide to the government and to society in general."
Creo Medical Group plc
Richard Rees (CFO)
+44 (0)1291 606 005
Cenkos Securities plc
+44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Joint Broker)
Numis Securities Limited (Joint Broker)
+44 (0)20 7260 1000
Freddie Barnfield / James Black / Duncan Monteith
Walbrook PR Ltd
Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Sam Allen / Phillip Marriage
Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082
About Creo Medical
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.
For more information, please refer to the website: www.creomedical.com
About the Royal Academy of Engineering
We are a charity delivering public benefit, a National Academy providing progressive leadership, and a Fellowship bringing together an unrivalled community of leaders from every part of engineering and technology.
HRH The Prince Philip, Duke of Edinburgh was our Senior Fellow, and instrumental in founding the Academy. HRH The Princess Royal and HRH The Duke of Kent are Royal Fellows.
For more information, please refer to the website: https://raeng.org.uk/
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.